羅妥木單抗

羅妥木單抗（INN：Robatumumab；開發代號：SCH 717454和MK-7454）是默克和先靈葆雅生產的單克隆抗體和抗腫瘤藥物。它與CD221（或稱胰島素樣生長因子1受體）結合。^[1]

針對結直腸癌、骨肉瘤和尤文氏肉瘤患者的II期臨床試驗已經完成。^[2]^[3]此後默克公司停止了該藥物的開發。^[4]

參考資料

^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 編. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. （原始內容存檔 (PDF)於2022-01-20）.
^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487 . PMID 27362300. doi:10.1002/pbc.26087.
^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. （原始內容存檔於2024-01-24）.